Company Profile
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat (AT-007), is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic Retinopathy.
Investor Presentation
Latest Quarterly Earnings
Press Releases
View All - News
Events
Nov 12, 2024 at 7:00 AM PST
Sep 18, 2024 at 10:20 AM EDT
Sep 10, 2024 at 3:45 PM EDT
View All - Events
Presentations
Sep 10, 2024
Mar 11, 2024